Clinical Trials Browser

Mitomycin × Clear all

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT04847063 2026-04-14

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Phase 1 Recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Gastrointestinal Neoplasms, Necrosis, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04929028 2026-04-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT06211764 2026-04-13

SunRISe-5

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06388720 2026-04-13

IMGeS

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT04779554 2026-04-01

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

Phase 2 Recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Colorectal Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04166318 2026-03-23

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Phase 2 Active not recruiting

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT07487168 2026-03-23

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

Phase 1 Not yet recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Peritoneal Diseases, Peritoneal Neoplasms, Colorectal Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05672108 2026-03-05

Phase II Trial of Lung Chemoemobolization

Phase 2 Recruiting

GastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Mediastinal Neoplasms, Pleural Neoplasms, Sarcoma

NCT03348969 2026-03-03

NICSA

Phase 4 Completed

Urinary Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06513065 2026-02-19

HIPEC-PMP

Phase 3 Recruiting

Pseudomyxoma Peritonei

NCT01815359 2026-02-05

ICARuS

Phase 2 Active not recruiting

Gastrointestinal

Appendiceal Neoplasms, Colorectal Neoplasms

NCT05838391 2026-02-03

Adaptive Radiation in Anal Cancer

Phase NA Recruiting

Gastrointestinal

Anus Neoplasms

NCT06774131 2026-01-16

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT06331299 2026-01-15

UTOPIA

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05902533 2025-12-18

REDEL

Phase 2/3 Active not recruiting

Gastrointestinal

Anus Neoplasms

NCT04329494 2025-12-10

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Phase 1 Recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT07271355 2025-12-09

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Phase 3 Not yet recruiting

Gastrointestinal

Appendiceal Neoplasms, Colorectal Neoplasms

NCT06783491 2025-11-24

FOXHIPECT4

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02369458 2025-11-18

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Phase 2 Completed

48 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT00183885 2025-10-30

A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma

Phase 2 Completed

76 enrolled 10 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04107077 2025-10-07

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

Phase 2 Recruiting

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT06781879 2025-10-03

COBRA-NMIBC

Phase 4 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Recurrence

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT02701088 2025-09-22

CANAL-IMRT-01

Phase 2 Active not recruiting

Gastrointestinal

Locally Advanced Anal Canal Cancer

NCT06207981 2025-09-02

KANALRAD

Phase 3 Recruiting

Gastrointestinal

Anus Neoplasms

NCT02363400 2025-08-19

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Phase 3 Terminated

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT04046133 2025-08-05

CORINTH

Phase 1 Active not recruiting

Gastrointestinal

Anus Neoplasms

NCT02106572 2025-07-23

TIM

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04200417 2025-05-16

Chemoembolization for Lung Tumors

Phase 1 Completed

Lung Metastases

NCT05024734 2025-03-11

GAIN INST

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT05494411 2025-02-28

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Carcinoma, Transitional Cell

NCT05874921 2025-02-28

uTRACT

Carcinoma, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Recurrence, Urogenital Neoplasms, Urologic Neoplasms

NCT03092518 2025-02-19

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

Phase 2 Completed

27 enrolled 13 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT06696794 2025-02-19

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT01167725 2024-12-27

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Phase 3 Terminated

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT02710734 2024-12-24

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2 Active not recruiting

Urothelial Carcinoma of the Bladder

NCT01905150 2024-12-11

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Phase 2 Completed

34 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04241185 2024-11-25

MK-3475-992

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03658304 2024-11-05

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

Phase 2 Completed

29 enrolled 11 charts

Carcinoma, Transitional Cell

NCT05243550 2024-11-04

ENVISION

Phase 3 Active not recruiting

240 enrolled 20 charts 3 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02040142 2024-10-24

HIPEC for Peritoneal Carcinomatosis

Phase 2 Completed

51 enrolled 12 charts

GastrointestinalGynecologic

Appendiceal Neoplasms, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Stomach Neoplasms, Colorectal Neoplasms